Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
$26.45-0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+77.5%
The outlook
Maze Therapeutics, Inc. currently reads as neutral based on strong buy — 1.1 avg of 11 analysts, below its 50- & 200-day averages, 33% of the way from its 52-week low to high, avg target +136% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 11 analysts
Price trendBelow its 50- & 200-day averages
52-week range33% of the way from its 52-week low to high
Price targetAvg target +136% vs current price
Analyst price target
~12-month · 11 analysts$62.55average target+136.5% vs now
Now $26.45
Low $46.00High $110.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.46B
52-wk high
$53.65
52-wk low
$12.81
50-day avg
$27.19
200-day avg
$34.58
Trailing P/E
—